文献速递免疫规划传染病防控与疫情报告

含或不含AS03佐剂的H9N2疫苗基础免疫在成人中的评价:一项I/II期随机试验

Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.
PubMed 文献 · Vaccine · 2017-07-15

该随机观察者盲法I/II期试验纳入420名18-64岁健康成人,比较10种H9N2灭活裂解病毒疫苗方案与安慰剂。所有含佐剂方案在第21天和第42天均超过免疫原性监管标准,血清保护率和血清转化率分别≥94.9%和≥89.8%(第21天)、100%和≥98.1%(第42天),佐剂方案可节省剂量4-8倍。

要点

  • 含AS03佐剂H9N2疫苗第21天血清保护率≥94.9%、血清转化率≥89.8%。
  • 第42天含佐剂方案血清保护率100%、血清转化率≥98.1%。
  • 佐剂方案较15µgHA无佐剂方案剂量节省4-8倍(3.75-1.9 vs 15µgHA)。

核心结论

  • 所有H9N2疫苗方案均具有免疫原性且安全性可接受,含佐剂方案可节省剂量4-8倍(3.75-1.9 vs 15µgHA)。

研究设计与样本

  • 随机、观察者盲法I/II期试验(ClinicalTrials.gov: NCT01659086),420名18-64岁健康成人接受10种H9N2灭活裂解病毒疫苗方案之一(每组30人)或生理盐水安慰剂(120人)。
  • H9N2组在第0、21天接种2剂15µg血凝素(HA)无佐剂,或1.9µgHA+AS03A、1.9µgHA+AS03B、3.75µgHA+AS03A、3.75µgHA+AS03B;第182天接种相同H9N2配方或安慰剂。
  • AS03为含α-生育酚(AS03A: 11.86mg;AS03B: 5.93mg)和角鲨烯的水包油乳剂佐剂系统;免疫原性和安全性评估至第546天。

主要发现

  • 所有含佐剂方案在第21天和第42天均超过免疫原性监管标准(血凝抑制试验),第21天血清保护率和血清转化率分别≥94.9%和≥89.8%,第42天分别为100%和≥98.1%。
  • 无佐剂疫苗也达到免疫原性标准,但几何平均滴度较低。
  • 第182天接种第三剂疫苗的组别出现回忆性免疫应答,血凝抑制和微量中和滴度大幅升高。
  • 含佐剂疫苗注射部位疼痛报告更频繁;未观察到疫苗相关严重不良事件。

关键数值与推荐

  • 含佐剂方案第21天血清保护率≥94.9%、血清转化率≥89.8%(血凝抑制试验)。
  • 含佐剂方案第42天血清保护率100%、血清转化率≥98.1%(血凝抑制试验)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Avian influenza A H9N2 strains have pandemic potential. METHODS: In this randomized, observer-blind study (ClinicalTrials.gov: NCT01659086), 420 healthy adults, 18-64years of age, received 1 of 10 H9N2 inactivated split-virus vaccination regimens (30 participants per group), or saline placebo (120 participants). H9N2 groups received 2 doses (days 0, 21) of 15µg hemagglutinin (HA) without adjuvant, or 1.9µgHA+AS03A, 1.9µgHA+AS03B, 3.75µgHA+AS03A, or 3.75µgHA+AS03B; followed by the same H9N2 formulation or placebo (day 182). AS03 is an adjuvant system containing α-tocopherol (AS03A: 11.86mg; AS03B: 5.93mg) and squalene in an oil-in-water emulsion. Immunogenicity (hemagglutination inhibition [HI] and microneutralization assays) and safety were assessed up to day 546. RESULTS: All adjuvanted formulations exceeded regulatory immunogenicity criteria at days 21 and 42 (HI assay), with seroprotection and seroconversion rates of ≥94.9% and ≥89.8% at day 21, and 100% and ≥98.1% at day 42. Immunogenicity criteria were also met for unadjuvanted vaccine, with lower geometric mean titers. In groups administered a third vaccine dose (day 182), an anamnestic immune response was elicited with robust increases in HI and microneutralization titers. Injection site pain was reported more frequently with adjuvanted vaccines. No vaccine-related serious adverse events were observed. CONCLUSIONS: All H9N2 vaccine formulations were immunogenic with a clinically acceptable safety profile; adjuvanted formulations were 4-8 times dose-sparing (3.75-1.9vs 15µgHA). TRIAL REGISTRATION: Registered on ClinicalTrials.gov: NCT01659086.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Madan A, Collins H, Sheldon E, et al. Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial. Vaccine. 2017. PMID: 28720281. doi:10.1016/j.vaccine.2017.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。